233676-45-4

Upstream product

• 233676-37-4 3-[(5-chloro-2-[(methylthiomethyl)oxy]-phenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one 
• 202821-81-6 3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)-phenyl]-1,3,4-oxadiazol-2(3H)-one 

Downstream Products

• 233676-36-3 3-[(5-Chloro-2-[[bis[phenylmethyl]phosphono]oxy]phenyl)-methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one 
• 234433-20-6 [4-chloro-2-[[5-[4-(trifluoromethyl)phenyl]-2,3-dihydro-2-oxo-1,3,4-oxadiazol-3-yl]methyl]phenoxy]methyl-4-(dimethylamino)butyrate 
• 573650-49-4 dimethylamino-acetic acid 4-chloro-2-[2-oxo-5-(4-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-3-ylmethyl]-phenoxymethyl ester 
• 573650-50-7 3-dimethylamino-propionic acid 4-chloro-2-[2-oxo-5-(4-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-3-ylmethyl]-phenoxymethyl ester 
• 233676-38-5 phosphoric acid dibenzyl ester 4-chloro-2-[2-oxo-5-(4-trifluoromethyl-phenyl)-[1,3,4]oxadiazol-3-ylmethyl]-phenoxymethyl ester 

Relevant academic research and scientific papers

Synthesis of water-Soluble prodrugs of BMS-191011: A maxi-K channel opener targeted for post-stroke neuroprotection

A variety of water-soluble prodrugs of BMS-191011 was synthesized and evaluated for solution state stability and rate of conversion to BMS-191011 in rat and human plasma. The deoxycarnitine ester prodrug (11c) was selected for clinical evaluation based on

PHOSPHATE DERIVATIVES OF DIARYL 1,3,4-OXADIAZOLONE

The present invention provides novel phosphate derivatives having the general formula wherein A, R1 and R2 are as defined herein, or a nontoxic pharmaceutically acceptable salt or solvate thereof and are useful in the treatment of disorders which are resp

PHOSPHATE DERIVATIVES OF DIARYL 1,3,4-OXADIAZOLONE

The present invention provides novel phosphate derivatives having the general formula wherein A, R 1 and R 2 are as defined herein, or a nontoxic pharmaceutically acceptable salt or solvate thereof and are useful in the treatment of disorders which are re